Lung Cancer
Gemcitabine and carboplatin used to treat non-small cell lung cancer
Published in Clinical Oncology Week, January 9th, 2006
"Gemcitabine plus carboplatin is a widely used regimen for the treatment of advanced NSCLC. This two drug combination is effective, with a favorable safety profile, and is well tolerated in the outpatient setting," scientists in England reported.
"Gemcitabine/carboplatin prolongs survival compared with gemcitabine alone, but with greater hematological toxicity. The combination regimen appears to be superior to or equally effective as other regimens including mitomycin, ifosfamide and cisplatin (MIC), cisplatin/vinblastine, gemcitabine/paclitaxel,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Breast Cancer
Weekly administration of docetaxel and paclitaxel used to treat breast cancer - Histiocytoma
Pulmonary resection for metastatic malignant fibrous histiocytoma deemed safe - Prognostics
Prognostic factors for rhabdoid tumor of the kidney delineated - Acute Lymphoblastic Leukemia
European study confirms efficacy of clofarabine in pediatric patients with ALL - Acute Myeloid Leukemia
Acute myeloid leukemia blasts regularly express PRR1 and PRR2 - Acute Myeloid Leukemia
Scientists may be able to use novel antibody to target specific cells leading to AML - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
